Trial · NCT04659044
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 42
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Alanine aminotransferase increased | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 10 |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 2 | 3 | 5 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 8 |
| other | Blood lactate dehydrogenase increased | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 2 | 3 | 2 |
| other | Cholesterol high | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 2 | 3 | 2 |
| other | Fatigue | General disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Fever | General disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Gastroesophageal reflux disease | Gastrointestinal disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | GGT increased | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Headache | Nervous system disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Hyperphosphatemia | Metabolism and nutrition disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 4 |
| other | Hypotension | Vascular disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Insomnia | Psychiatric disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Lymph node pain | Blood and lymphatic system disorders | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 1 | 3 | 1 |
| other | Lymphocyte count decreased | Investigations | Treatment (Rituximab, Polatuzumab Vedotin, Venetoclax) | 2 | 3 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04659044/events